Amphastar Pharmaceuticals (AMPH) Non-Current Deffered Revenue (2013 - 2017)

Amphastar Pharmaceuticals' Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at $1.2 million for Q3 2017.

• On a quarterly basis, Non-Current Deffered Revenue rose 623.21% year-over-year to $1.2 million in Q3 2017; TTM through Sep 2017 was $1.2 million, a 623.21% increase from a year earlier, with the FY2016 full-year figure at $97000.0, down 92.76% from the prior year.
• Non-Current Deffered Revenue grew to $1.2 million in Q3 2017 per AMPH's latest filing, from $423000.0 in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $2.6 million in Q4 2013 and bottomed at $97000.0 in Q4 2016.
• The 5-year median for Non-Current Deffered Revenue is $1.3 million (2015), against an average of $1.3 million.
• Across the five-year window, Non-Current Deffered Revenue tumbled 92.76% in 2016 and surged 623.21% in 2017, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $2.6 million in 2013, then fell by 24.5% to $2.0 million in 2014, then tumbled by 32.44% to $1.3 million in 2015, then tumbled by 92.76% to $97000.0 in 2016, then jumped by 1152.58% to $1.2 million in 2017.
• Per Business Quant, the three latest AMPH Non-Current Deffered Revenue figures stand at $1.2 million (Q3 2017), $423000.0 (Q2 2017), and $280000.0 (Q1 2017).